Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

To study safety, tolerability, and comparative pharmacokinetics of STS101, in a dry powder formulation for nasal administration vs intramuscular (IM) DHE and DHE liquid nasal spray (MIGRANAL®) in healthy adult subjects.

Next Previous
Search
Trial Profile

To study safety, tolerability, and comparative pharmacokinetics of STS101, in a dry powder formulation for nasal administration vs intramuscular (IM) DHE and DHE liquid nasal spray (MIGRANAL®) in healthy adult subjects.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 30 May 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dihydroergotamine mesilate (Primary) ; Dihydroergotamine mesilate (Primary)
  • Indications Migraine
  • Focus Adverse reactions

    • Most Recent Events

    • 26 Apr 2022 Results comparing the PK and safety profile of STS101, incorporating an optimized delivery device, with DHE LNS and IM DHE presented at the 74th Annual Meeting of the American Academy of Neurology 2022
    • 10 Mar 2020 Results published in peer-reviewed journal, HEADACHE: The Journal of Head and Face Pain.
    • 22 Nov 2019 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top